# A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

> **NCT04166006** · PHASE2 · RECRUITING · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 51 (estimated)

## Conditions studied

- Head Neck Tumors
- Neuroendocrine Tumors
- Soft Tissue Sarcoma
- Rare Cancer
- Vaccination

## Interventions

- **BIOLOGICAL:** Autologous DC vaccine
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT04166006
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-12-12
- **Primary completion:** 2027-04
- **Final completion:** 2031-12
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04166006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04166006, "A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04166006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*